secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2026-08-03T20:30:21+00:00
Accession:  0001214659-26-009469
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 3.01, 3.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro Enters $25M Securities Purchase Agreement and Reports Nasdaq Non-Compliance
--------------------------------------------------------------------------------

- Entered securities purchase agreement with Ault Lending for up to $25M in Series D convertible preferred stock; initial closing of $7.5M on July 31, 2026.
- Notified Nasdaq of non-compliance with majority independent board standard following death of independent director Lynne Fahey McGrath on July 20, 2026; cure period until July 20, 2027.
- Filed Series D Certificate of Designation with Delaware Secretary of State on July 31, 2026.
- Purchaser Ault Lending is an affiliate of the Company; conversion price floor at $0.2668 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926009469/0001214659-26-009469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926009469/az7312618k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-26-009469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer